I am a passionate healthcare and pharmaceutical strategist with proven experience creating “value from vision”. I have up to 28 years of pharmaceutical industry experience, the majority as a New Product Strategy and Planning professional.
I am currently Executive Director, Head of Global Patient Insights & Solutions (GPIS) for Alexion, AstraZeneca Rare Disease. My team is part of Alexion’s Patient Experience team, which also includes our country-level Patient Advocate colleagues. GPIS creates value for Alexion by partnering with external stakeholders (patients, caregivers, physicians, patient advocacy groups) to develop strategies and/or solutions that will accelerate results to patients living with rare disease. GPIS ensures that Alexion colleagues who work in all parts of the drug development timeline have a deep and empathetic understanding for the patient experience. Having that experience, Alexion colleagues can better identify strategies or solutions that deliver the therapies that patients, physicians, and other stakeholders need.
Prior to joining Alexion, I held several roles as a member of the Pfizer Inc. Commercial organisation. Specifically, I was the New Products Commercial lead for three currently marketed products including a treatment for lung and breast cancer, rheumatoid arthritis, and an anticoagulant. I received an AB degree in Biochemistry from Smith College (Northampton, MA), an MBA in Strategic Planning & Accounting from the Katz Graduate School of Business, University of Pittsburgh, and an Executive MBA Certificate in Strategic Finance from the Harvard Business School.
Our goal as pharmaceutical professionals is to translate innovative science into meaningful medicines. This doesn’t happen by accident. We achieve this goal by actively listening to patients and all our stakeholders to uncover how we can best meet their needs and expectations. This is what inspires me and what gets me up in the morning, every single workday. Actively partnering with and listening to key external stakeholders is how we deliver for patients.
Alexion Excellence Award
Alexion Living the Values Award
Alexion Guiding Star Award
2014 - 2020
Joined Alexion to create the New Product Strategy Team; Head of New Product Strategy; Head of Business Development Commercial Team; Commercial Lead for numerous business development transactions including Wilson Therapeutics, Syntimmune, Achillion, and Caelum Biosciences, Alexion
Named on two patents for use of modified mRNA in treatment of two rare diseases (propionic acidemia and progressive familial intrahepatic cholestasis)
2010 - 2013
Director/Team Leader, Global Business Development – Commercial, Pfizer; Led BD Commercial Team for Pfizer Primary Care business unit; Business Development Commercial lead for successful Pfizer-BMS anticoagulant therapy co-promote transaction
Veeva ID: Z4-42742
Date of preparation: March 2022